We are live on
!
Find out more
Deep Track Capital Portfolio holdings
AUM
$6.87B
Turnover
41.46%
1-Year Est. Return
205.24%
This Fund
S&P 500
This Quarter
Est. Return
+8.81%
1 Year Est. Return
+205.24%
3 Year Est. Return
+440.18%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$6.12B
AUM Growth
+$515M
(+9.2%)
Cap. Flow
+$659M
Cap. Flow
% of AUM
10.76%
Top 10 Holdings %
Top 10 Hldgs %
53.58%
Holding
69
New
14
Increased
25
Reduced
14
Closed
6
Avg Time Held Equity + Options
1.1
years
Top 10 Avg Time Held Equity + Options
0.7
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
1.1
years
Top 10 Avg Time Held Equity only
0.7
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alumis Inc
ALMS
|
+$169M |
| 2 |
Nuvalent
NUVL
|
+$140M |
| 3 |
Ocular Therapeutix
OCUL
|
+$111M |
| 4 |
Genmab
GMAB
|
+$110M |
| 5 |
Vera Therapeutics
VERA
|
+$55.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Dynavax Technologies
DVAX
|
+$242M |
| 2 |
Cytokinetics
CYTK
|
+$125M |
| 3 |
Apellis Pharmaceuticals
APLS
|
+$69.3M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
+$67.1M |
| 5 |
Maze Therapeutics
MAZE
|
+$33.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 79.14% |
| 2 | Miscellaneous | 20.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Compass Pathways
CMPS
$1.61B
| $67.3M | 1.1% |
12,161,496
+4,827,173
| +66% | +$32.5M |
2025 Q1
4 quarters
|
|
|
27
BioMarin Pharmaceuticals
BMRN
$10.8B
| $65M | 1.06% |
1,150,000
-1,150,000
| -50% | -$67.1M |
2025 Q3
2 quarters
|
|
28
BridgeBio Pharma
BBIO
$13.1B
| $62.5M | 1.02% |
841,445
+31,303
| +4% | +$2.27M |
2024 Q4
5 quarters
|
|
29
Immunocore
IMCR
$1.52B
| $58.2M | 0.95% |
1,931,884
-72,094
| -4% | -$2.33M |
2024 Q4
5 quarters
|
|
30
Tango Therapeutics
TNGX
$3.83B
| $57.5M | 0.94% |
2,750,000
+295,438
| +12% | +$4.11M |
2025 Q3
2 quarters
|
|
31
Definium Therapeutics
DFTX
$4.6B
| $56.7M | 0.93% |
3,000,000
+1,323,460
| +79% | +$22.5M |
2024 Q1
8 quarters
|
|
32
DELISTED
Terns Pharmaceuticals
TERN
| $56.6M | 0.92% |
1,073,877
+304,829
| +40% | +$12.5M |
2023 Q2
11 quarters
|
|
33
Geron
GERN
$790M
| $47.3M | 0.77% |
31,720,278
-790,993
| -2% | -$1.2M |
2022 Q4
13 quarters
|
|
34
ANI Pharmaceuticals
ANIP
$1.66B
| $46.1M | 0.75% |
600,000
+122,316
| +26% | +$9.55M |
2023 Q2
11 quarters
|
|
35
CorMedix
CRMD
$581M
| $42.6M | 0.7% |
6,274,076
+1,000,000
| +19% | +$7.39M |
2025 Q3
2 quarters
|
|
36
DELISTED
AtaiBeckley Inc
ATAI
| $42.5M | 0.69% |
12,000,000
+7,322,711
| +157% | +$27.6M |
2025 Q4
1 quarter
|
|
37
Celldex Therapeutics
CLDX
$2.27B
| $40.7M | 0.67% |
1,283,979
-616,759
| -32% | -$16.8M |
2024 Q4
5 quarters
|
|
38
Cogent Biosciences
COGT
$5.12B
| $38.5M | 0.63% |
1,000,000
+546,898
| +121% | +$20.2M |
2025 Q4
1 quarter
|
|
39
Corvus Pharmaceuticals
CRVS
$829M
| $36.5M | 0.6% |
+2,491,539
| New | +$39.8M |
2026 Q1
0 quarters
|
|
40
Dyne Therapeutics
DYN
$2.86B
| $36.3M | 0.59% |
2,000,000
-650,000
| -25% | -$11.2M |
2025 Q3
2 quarters
|
|
41
DELISTED
Soleno Therapeutics
SLNO
| $36.1M | 0.59% |
1,078,710
+78,710
| +8% | +$3.09M |
2025 Q4
1 quarter
|
|
42
Aclaris Therapeutics
ACRS
$514M
| $35M | 0.57% |
+9,345,000
| New | +$31.5M |
2026 Q1
0 quarters
|
|
43
Veradermics Inc
MANE
$4.81B
| $31.6M | 0.52% |
+500,000
| New | +$25.2M |
2026 Q1
0 quarters
|
|
44
Verastem
VSTM
$836M
| $30.4M | 0.5% |
5,740,850
| – | – |
2025 Q4
1 quarter
|
|
45
enGene Therapeutics
ENGN
$115M
| $29.8M | 0.49% |
4,377,572
| – | – |
2024 Q1
8 quarters
|
|
46
Viridian Therapeutics
VRDN
$2.22B
| $27.3M | 0.45% |
1,393,944
-1,130,889
| -45% | -$33.6M |
2021 Q4
17 quarters
|
|
47
X4 Pharmaceuticals
XFOR
$262M
| $26.2M | 0.43% |
6,339,535
+1,325,874
| +26% | +$4.97M |
2025 Q3
2 quarters
|
|
48
Solid Biosciences
SLDB
$615M
| $25.7M | 0.42% |
+3,565,062
| New | +$22.9M |
2026 Q1
0 quarters
|
|
49
Enanta Pharmaceuticals
ENTA
$334M
| $24.7M | 0.4% |
1,956,867
| – | – |
2025 Q4
1 quarter
|
|
50
DELISTED
Apogee Therapeutics
APGE
| $24M | 0.39% |
+285,000
| New | +$20.7M |
2026 Q1
0 quarters
|
|
Similar funds
Deep Track Capital's Q1 2026 Portfolio in Review
As of Q1 2026, Deep Track Capital held 69 positions worth $6.12B, up 9.2% from $5.61B the previous quarter. Its ten largest holdings account for 54% of the portfolio.
Deep Track Capital deployed $659M of net new capital in Q1 2026, opening 14 new positions and adding to 25 existing holdings. Its largest new stake was Alumis Inc: 6,772,595 shares worth $149M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 78% a quarter earlier, followed by Miscellaneous.
On the sell side, the largest reduction was Cytokinetics, an estimated $125M trimmed.
- Deep Track Capital's largest Q1 2026 buy was Alumis Inc: 6,772,595 shares worth $149M.
- Deep Track Capital added most to Ocular Therapeutix in Q1 2026, an estimated $111M increase.
- Deep Track Capital's biggest Q1 2026 reduction was Cytokinetics, cutting an estimated $125M.
- Deep Track Capital fully exited Dynavax Technologies in Q1 2026, selling an estimated $242M.
- Deep Track Capital's ten largest holdings make up 54% of its $6.12B portfolio in Q1 2026.
- Deep Track Capital opened 14 new positions and closed 6 in Q1 2026.
- Deep Track Capital's portfolio value rose 9.2% quarter-over-quarter to $6.12B.
Based on Deep Track Capital's 13F filing for Q1 2026, filed 15 May 2026.